Unknown

Dataset Information

0

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.


ABSTRACT:

Background

To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody against angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).

Methods

Colo205 colon cancer xenografts were imaged before and 5 days after treatment with a single 10?mg?kg(-1) dose of either vanucizumab, bevacizumab (anti-human VEGF-A), LC06 (anti-murine/human Ang-2) or omalizumab (anti-human IgE control). Volumetric response was assessed using T2-weighted MRI, and diffusion-weighted, dynamic contrast-enhanced (DCE) and susceptibility contrast MRI used to quantify tumour water diffusivity (apparent diffusion coefficient (ADC), × 10(6)?mm(2)?s(-1)), vascular perfusion/permeability (K(trans), min(-1)) and fractional blood volume (fBV, %) respectively. Pathological correlates were sought, and preliminary gene expression profiling performed.

Results

Treatment with vanucizumab, bevacizumab or LC06 induced a significant (P<0.01) cytolentic response compared with control. There was no significant change in tumour ADC in any treatment group. Uptake of Gd-DTPA was restricted to the tumour periphery in all post-treatment groups. A significant reduction in tumour K(trans) (P<0.05) and fBV (P<0.01) was determined 5 days after treatment with vanucizumab only. This was associated with a significant (P<0.05) reduction in Hoechst 33342 uptake compared with control. Gene expression profiling identified 20 human genes exclusively regulated by vanucizumab, 6 of which are known to be involved in vasculogenesis and angiogenesis.

Conclusions

Vanucizumab is a promising antitumour and antiangiogenic treatment, whose antivascular activity can be monitored using DCE and susceptibility contrast MRI. Differential gene expression in vanucizumab-treated tumours is regulated by the combined effect of Ang-2 and VEGF-A inhibition.

SUBMITTER: Baker LCJ 

PROVIDER: S-EPMC5023775 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.

Baker Lauren C J LCJ   Boult Jessica K R JKR   Thomas Markus M   Koehler Astrid A   Nayak Tapan T   Tessier Jean J   Ooi Chia-Huey CH   Birzele Fabian F   Belousov Anton A   Zajac Magdalena M   Horn Carsten C   LeFave Clare C   Robinson Simon P SP  

British journal of cancer 20160816 6


<h4>Background</h4>To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody against angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).<h4>Methods</h4>Colo205 colon cancer xenografts were imaged before and 5 days after treatment with a single 10 mg kg(-1) dose of either vanucizumab, bevacizumab (anti-human VEGF-A), LC06 (anti-  ...[more]

Similar Datasets

| S-EPMC4843473 | biostudies-literature
| S-EPMC7485732 | biostudies-literature
| S-EPMC5547238 | biostudies-literature
| S-EPMC2584674 | biostudies-literature
2016-06-07 | GSE80683 | GEO
| S-EPMC8678608 | biostudies-literature
| S-EPMC11305399 | biostudies-literature
| S-EPMC2949115 | biostudies-other
| S-EPMC5082561 | biostudies-other
| S-EPMC4968104 | biostudies-literature